Results 101 to 110 of about 13,617 (225)

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database

Scientific Reports
Omalizumab is a biologic agent used in the management of allergic conditions, including asthma and urticaria. Although the efficacy of omalizumab has been well established, its safety profile is primarily derived from clinical trials with limited sample ...
Yongfu Song, Zhuang Wang, Na Wang, Xiaofei Xie, Tieshi Zhu, Yongji Wang   +5 more
doaj   +1 more source

Omalizumab in Chronic Urticaria : an Italian Survey

, 2018
Omalizumab is approved for use in chronic spontaneous urticaria (CSU); however, it is not approved for chronic inducible urticaria (CIndU). The aim of the present study was to assess the effectiveness of omalizumab in treating CSU and CIndU in Italy ...
R. R. Z. Conic, G. Damiani, Colli L, L. Colli, A. M. Offidani, S. Ferrucci, Ferrucci S, E. Martina, Martina E, Offidani AM, Damiani G, Pigatto PDM, M. Diani, Diani M, P. D. M. Pigatto, DAMIANI GIOVANNI, Conic RRZ   +16 more
core   +1 more source

Differential Effects of Benralizumab and Mepolizumab on Pro‐Resolving Mediators

Allergy, EarlyView.
Jaime Bernaola, José Antonio Cañas, Álvaro Arranz‐Fragua, José Manuel Rodrigo‐Muñoz, Daniel Rodríguez‐González, Antonio Serrano‐Santiago, Gema Guillén‐Sánchez, Alma Martínez Fernández, Marcela Valverde‐Monge, Diana Betancor, Erwin Javier Pinillos‐Robles, Claudia Rodríguez‐Busto, María Jesús Rodríguez‐Nieto, Joaquín Sastre, Victoria del Pozo   +14 more
wiley   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source

Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium

ERJ Open Research, 2019
Background Guidelines recommend omalizumab in patients with uncontrolled severe allergic asthma. We investigated real-life use of omalizumab, the proportion of patients fulfilling eligibility criteria, its costs and its effectiveness.
Katia M.C. Verhamme, Catherine Lucet, Alain Van Meerhaeghe, Guy G.O. Brusselle, Marie-Laurence Lambert   +4 more
doaj   +1 more source

Efficacy of Omalizumab in Indolent Systemic Mastocytosis

, 2019
Background. Systemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs.
Lisa Hicks, Slapnicar, Calum, Calum Slapnicar, Peter Vadas, Vadas, Peter, Trinkaus, Martina, Hicks, Lisa, Martina Trinkaus   +7 more
core   +1 more source

A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data

Педиатрическая фармакология, 2016
Background: Omalizumab is the first and yet the only biopreparation for asthma which combines high efficiency and high cost. The clinical-economic expediency of using omalizumab in asthmatic children has not been previously studied in Russia.Objective ...
A. S. Kolbin, L. S. Namazova-Baranova, E. A. Vishneva, M. Y. Frolov, T. L. Galankin, A. A. Alekseeva, E. A. Dobrynina   +6 more
doaj   +1 more source

Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history

, 2018
Farnaz Tabatabaian, Dennis K Ledford Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA Abstract: Asthma is a heterogeneous syndrome with numerous underlining ...
Tabatabaian F, Ledford DK
core  

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

, 2017
Background: Omalizumab is licensed as add-on therapy for patients with severe allergic asthma. Response is in most studies scored by the physician's global evaluation of treatment effectiveness (GETE).
Snelder, S. M., S. M. Snelder, Braunstahl, G. J., E. J. M. Weersink, Weersink, E. J. M., G. J. Braunstahl   +5 more
core   +1 more source

CH50 as a Clinically Useful Biomarker of Disease Activity and Antihistamine Resistance in Chronic Spontaneous Urticaria: An Observational Ambispective Single‐Center Study

International Journal of Dermatology, EarlyView.
Personalized CSU care guided by CH50. ABSTRACT Background Chronic spontaneous urticaria (CSU) is frequently refractory to guideline‐based therapy, highlighting the need for predictive biomarkers. Dysregulation of the complement system has been implicated in CSU severity, but global complement activity has not been systematically evaluated.
Nidia Planella‐Fontanillas, Emilio Berna‐Rico, David Pesqué, Evelyn Andrades, Silvia Sánchez, Paloma Torres‐Bosó, Ramon Gimeno, Fernando Gallardo, Ramon M. Pujol, Ana M. Giménez‐Arnau   +9 more
wiley   +1 more source